GSK shares fell after the U.K. drugmaker said it would stop working on an experimental treatment for chronic cough after ...
By Bhanvi Satija and Prerna Bedi July 17 (Reuters) - GSK will halt development of an experimental drug to treat refractory ...
The FDA said the detection of Cyclospora in iceberg lettuce from Taylor Farms, initially linked to a multistate outbreak of ...
Three years after buying Bellus Health and its chronic cough candidate camlipixant for around $2 billion, GSK is abandoning ...
Stories by SWNS on MSN
Parrot keeps mimicking owner’s dad’s chronic cough
A Congo African grey parrot named Jack has become known for repeatedly imitating the chronic cough of her owner’s father, who ...
Sonothera's ultrasound gene therapy delivery, a new Alzheimer's drug controversy, and more biotech news from The Readout ...
GlobalData on MSN
GSK’s drops chronic cough drug, dampening $2bn Bellus Health bid
The British pharma company will discontinue camlipixant’s late-stage RCC programme, though it will continue the drug’s ...
GSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as the key 2026 catalyst for the ...
Trevi Therapeutics grew its share prices by 9.85 percent on Friday to finish at $19.07 apiece, after management underscored ...
Climate change, pollution, and longer allergy seasons are increasing persistent coughs, slowing recovery, and raising ...
Chronic cough is defined as cough lasting more than eight weeks and is associated with significant physical, social, and psychosocial burden. It is estimated that approximately 27 million adults in ...
U.S. stock futures dip amid AI chip selloff. Here are some stocks to watch on the day.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results